C2i Genomics partners with Twist Bioscience to launch reference material for genome-wide cancer detection

Cancer intelligence company C2i Genomics and Twist Bioscience recently announced a collaboration to develop genome-wide cancer reference materials

A major obstacle faced by diagnostic laboratories and regulatory agencies in cancer diagnosis today is the lack of standardized reference samples for analytical validation when performing genome-wide analysis in the laboratory

Under the collaboration agreement, C2i will utilize artificial intelligence (AI) to identify a large number of variants associated with cancer signatures across the genome

Dr.

Reference standards can also be used to train samples and adjust the C2i algorithm for analysis of patient samples

Asaf Zviran, CEO and co-founder of C2i Genomics, said: "C2i is committed to advancing the availability of genome-wide cancer detection and monitoring, thereby supporting researchers and clinicians to improve the treatment of patients with oncology

Before the partnership with Twist, C2i had shown strong momentum over the past year

About C2i Genomics

Founded in 2019, C2i Genomics has created the world's leading intelligent platform for cancer therapy that utilizes low starting volumes of blood (only 2mL of blood) for whole-genome sequencing, capable of providing 100x higher detection sensitivity than other liquid biopsy companies

About Twist Bioscience

Twist Bioscience is a leading and fast-growing synthetic biology and genomics company developing game-changing DNA synthesis platforms to advance the industrialization of bioengineering